Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
102.8 PLN | +1.38% | +0.98% | +7.19% |
03-20 | PCC Rokita SA Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
2023 | PCC Rokita SA Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 | CI |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
Strengths
- The company is one of the best yield companies with high dividend expectations.
- Upward revisions of sales forecast reflect a renewed optimism among the analysts covering the stock.
- Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
- The company's earnings growth outlook lacks momentum and is a weakness.
- With an expected P/E ratio at 42.13 and 12.49 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- The company is highly valued given the cash flows generated by its activity.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
Ratings chart - Surperformance
Sector: Specialty Chemicals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+7.19% | 511M | - | ||
+1.61% | 49.2B | A- | ||
+16.33% | 41.24B | B+ | ||
+18.68% | 25.89B | A- | ||
+12.78% | 19.81B | C+ | ||
+0.85% | 17.48B | B+ | ||
-21.87% | 15.86B | A- | ||
+2.32% | 15.35B | B+ | ||
-10.29% | 15.23B | C+ | ||
-22.30% | 13.36B | A- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- PCR Stock
- Ratings PCC Rokita SA